Lou Bock

Bio

Lou is an industry veteran and is focused on identifying emerging biopharmaceutical, device and platform technology companies. Lou sits on the Boards of Ascenta Therapeutics, Century Hospice, diaDexus, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVP's investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN), and Somaxon (NASDAQ: SOMX). Lou joined Scale Venture Partners in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead's approved antiviral drug, Vistide, and was responsible for the discovery of Gilead's novel thrombin aptamer. Previous to Gilead, he was a research associate at Genentech. MBA from California State University, San Francisco and a BS in Biology from California State University, Chico.